This laboratory proposes to continue its studies into the molecular basis and treatment of retinoblastoma and uveal melanoma utilizing new molecular genetic techniques, immunohistochemical staining, and classic morphologic techniques. Specifically, we plan the following studies: 1. We wish to identify each of the genetic lesions involved in the initiation and progression of retinoblastoma. We first will determine what the cellular genes responsible for retinoblastoma developing in transgenic mice carrying the human papillomaviral (HPV) transgene E6 and E7 are, and how these differ from the genetic alterations responsible for human retinoblastoma 2. We will assess the role of N-myc in retinoblastoma transgenic mice by producing and characterizing IRBP-N-myc transgenic mice and opsin-N- myc mice 3. We will continue our study of 1,25 dihydroxy-16ene-23yneD3(16,23- vitaminD3) in transgenic mouse models and athymic nude mouse models to evaluate its efficacy in treatment of human retinoblastoma, hopefully in preparation of a human clinical trial. 4. We will evaluate the effectiveness of recombinant Herpes simplex virus (HSV) attenuated for neurovirulence in transgenic retinoblastoma mice. We will determine the effect of the mutants on the normal retina and on tumor parameters in transgenic retinoblastoma mice. 5. We will characterize pigmented tumors developing in the eyes of mice expressing SV40-T antigen (SV40-Tag) under the control of the mouse tyrosinase gene, and establish the relevance of these mice as a model for human uveal melanoma.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
3R01EY001917-24S3
Application #
6211629
Study Section
Visual Sciences C Study Section (VISC)
Program Officer
Dudley, Peter A
Project Start
1976-07-01
Project End
2000-11-30
Budget Start
1998-02-01
Budget End
2000-11-30
Support Year
24
Fiscal Year
2000
Total Cost
$291,983
Indirect Cost
Name
University of Wisconsin Madison
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Burris, Christopher K H; Raven, Meisha L; Rodriguez, Maria E et al. (2017) Bilateral Primary Mucinous Carcinoma of the Eyelid. Ophthal Plast Reconstr Surg 33:S72-S73
Rodriguez, Maria E; Burris, Christopher K; Kauh, Courtney Y et al. (2017) A Conjunctival Melanoma Causing Bloody Tears. Ophthal Plast Reconstr Surg 33:e77
Kulkarni, A D; van Ginkel, P R; Darjatmoko, S R et al. (2009) Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol 93:1105-8
van Ginkel, Paul R; Yang, William; Marcet, Marcus M et al. (2007) 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J Neurooncol 85:255-62
Albert, Daniel M; Scheef, Elizabeth A; Wang, Shoujian et al. (2007) Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 48:2327-34
Tolleson, William H; Doss, Jason C; Latendresse, John et al. (2005) Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. Arch Ophthalmol 123:1088-94
Albert, Daniel M; Kumar, Amit; Strugnell, Stephen A et al. (2004) Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch Ophthalmol 122:1365-9
Albert, Daniel M; Kumar, Amit; Strugnell, Stephen A et al. (2004) Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch Ophthalmol 122:1357-62
Cullinan, Amy E; Lindstrom, Mary J; Sabet, Sina et al. (2004) Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model. Curr Eye Res 29:167-72
Audo, Isabelle; Darjatmoko, Soesiawati R; Schlamp, Cassandra L et al. (2003) Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. Invest Ophthalmol Vis Sci 44:4192-9

Showing the most recent 10 out of 84 publications